AbbVie closes $10.9 billion deal to buy Apogee Therapeutics and strengthen immunology

A significant transaction in the pharmaceutical sector was revealed on Monday, with AbbVie confirming the acquisition of Apogee Therapeutics. The pharmaceutical giant will shell out $10.9 billion in cash for the biotechnology company, aiming to strengthen its line of immunology products for the next generation. This strategic move comes at a crucial time for AbbVie as it seeks to diversify and innovate following the exclusivity period for its flagship drug, Humira.
AbbVie’s proposal to Apogee Therapeutics shareholders calls for payment of US$135.11 per share. This value represents a considerable premium of 49.49% over the shares’ closing price last Thursday. In pre-market trading, Apogee shares were already priced at US$136.3, indicating the market’s positive reception of the announcement.
The completion of the deal will guarantee AbbVie the rights to zumilokibart, Apogee’s main compound under development. This treatment, still in the experimental phase, is focused on various inflammatory conditions. Targeted applications include moderate to severe atopic dermatitis and asthma, representing a potential expansion for AbbVie’s immune therapies and a promising advancement for patients with these illnesses.







